Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.
Antithrombotic,thrombolytic,and Anticoagulants         COAGULATION CASCADE
Drug                                         Duration(Half                   Antigenicity Specifitycharacteristics        ...
CLINICAL USES OF FIBRINOLYTIC DRUGSIN THE FOLLOWING EMERGENCE CASES:1) STROKE.2) Multiple Pulmonary thromboembolism.3) myo...
CLASSIFICATION OF ANTICOAGULANTSA) IN VITRO:1- HEPARIN2-Ca- COMPLEX AGENTS: a) Na-Citrate                         b) Na-Ox...
MECHANISM OF ACTION OF HEPARIN
Drug        Major    Setting   Interaven- Anticoa-  Bio-characteri-   Adverse     for         ous     gulant  avail-   sti...
CLINICAL USES OF HEPARIN1) Deep vein thrombosis.2) Pulmonary thromboembolism.3) myocardial infarction.4)Before and after t...
A) ADVERSE REACTIONS(side-and toxic effects):1) Hypersensitivity reactions.2) Hemorrhage.3)Thrombocytopenia.4) Alopecia. 5...
DRUG DRUG – INTERACTIONS OF WARFARIN1)Increase the effect of warfarin: a) Use of metronidazol or erythromcin or cimetidine...
MECHANISM OF ACTION OF VIT.K
Anticoauglants
Anticoauglants
Anticoauglants
Anticoauglants
Nächste SlideShare
Wird geladen in …5
×

Anticoauglants

Anticoauglants

  • Loggen Sie sich ein, um Kommentare anzuzeigen.

Anticoauglants

  1. 1. Antithrombotic,thrombolytic,and Anticoagulants COAGULATION CASCADE
  2. 2. Drug Duration(Half Antigenicity Specifitycharacteristics life) in minutes Streptokinase YES NO About 30 Urokinase NO NO About 20 Altaplase NO YES About 10
  3. 3. CLINICAL USES OF FIBRINOLYTIC DRUGSIN THE FOLLOWING EMERGENCE CASES:1) STROKE.2) Multiple Pulmonary thromboembolism.3) myocardial infarction. ***** BODY FACTORS THAT: *****1) Increase The Effect Of Warfarin:a) Hepatic Diseases. b) Hypothyroidism2) Decrease The Effect Of Warfarin:a) Hereditary Resistance b) Hyperthyroidism
  4. 4. CLASSIFICATION OF ANTICOAGULANTSA) IN VITRO:1- HEPARIN2-Ca- COMPLEX AGENTS: a) Na-Citrate b) Na-Oxalate C)Na-EdetateB) IN VIVO:1- HEPARIN , LMWs ( e.g. enoxaparin,deltaparin )and Heparinoides (e.g.Danaparoid and Lepirudin)2-ORAL ANTICOAGULANTS:
  5. 5. MECHANISM OF ACTION OF HEPARIN
  6. 6. Drug Major Setting Interaven- Anticoa- Bio-characteri- Adverse for ous gulant avail- stics effect therapy Half-life response ability Frequent Heparin Hospital Two hours Variable 20% Bleeding low Hospitalmolecular Less Predict- and out- Four hours 90% weight Bleeding able patient heparin
  7. 7. CLINICAL USES OF HEPARIN1) Deep vein thrombosis.2) Pulmonary thromboembolism.3) myocardial infarction.4)Before and after thorax , orthopedic surgery.5) Unstable angina.6) In extracorporeal Circulation.
  8. 8. A) ADVERSE REACTIONS(side-and toxic effects):1) Hypersensitivity reactions.2) Hemorrhage.3)Thrombocytopenia.4) Alopecia. 5)Osteoporosis ( prolonged use of heparin ).B)CONTRAINDICATIONS :1)Heparin Hypersensitivity.2) Patients with active bleeding or bleeding tendencies.
  9. 9. DRUG DRUG – INTERACTIONS OF WARFARIN1)Increase the effect of warfarin: a) Use of metronidazol or erythromcin or cimetidine. b) Use of aspirin or sulfonamide or indomethacin. c) Use of oral broad spectrum antimicrobials:ampicillin or tetracycline. d) use of antithrombotic drugs : clopediogrel orteclopedin or aspirin. e) Use of liquid paraffin.2) Decrease the effect of warfarin:a) Use of inducers : phenobarbitures or rifampin.b) Use of vitamin K.c) Use of cholestyramine.d) Use of oral contraceptives.
  10. 10. MECHANISM OF ACTION OF VIT.K

×